<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01633489</url>
  </required_header>
  <id_info>
    <org_study_id>ALX-LALD-501</org_study_id>
    <nct_id>NCT01633489</nct_id>
  </id_info>
  <brief_title>Lysosomal Acid Lipase (LAL) Deficiency Registry</brief_title>
  <acronym>ALX-LALD-501</acronym>
  <official_title>An Observational Disease and Clinical Outcomes Registry of Patients With Lysosomal Acid Lipase (LAL) Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational, multi-center, international disease registry designed to collect
      longitudinal data and create a knowledge base that will be utilized to improve the care and
      treatment of patients with LAL Deficiency. Participation in the Registry by both physicians
      and patients is voluntary.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lysosomal Acid Lipase (LAL) Deficiency is a rare autosomal recessive lysosomal storage
      disorder (LSD) that is caused by a marked decrease of lysosomal acid lipase (LAL), the enzyme
      that breaks down cholesteryl esters and triglycerides in the lysosomes.

      Lysosomal Acid Lipase Deficiency presenting in infants (historically called Wolman Disease)
      is a medical emergency with rapid disease progression over a period of weeks that is
      typically fatal within the first 6 months of life. More commonly, LAL Deficiency presents in
      children and adults and this presentation has been historically called Cholesteryl Ester
      Storage Disease (CESD). In general, data on the prevalence of LAL Deficiency are limited, and
      the overall prevalence of the disease in the population is unclear.

      For all presentations, LAL Deficiency is associated with significant morbidity and mortality.
      Deficient LAL enzyme activity results in the lysosomal accumulation of cholesteryl esters and
      triglycerides. In the liver, this accumulation leads to hepatomegaly, increased hepatic fat
      content, transaminase elevation signaling chronic liver injury, and progression to fibrosis,
      cirrhosis, and complications of end stage liver disease. In the spleen, LAL Deficiency
      results in splenomegaly, anemia, and thrombocytopenia. Lipid accumulation in the intestinal
      wall leads to malabsorption and growth failure. Dyslipidemia is common with elevated low
      density lipoprotein (LDL) and triglycerides and low high density lipoprotein (HDL),
      associated with increased liver fat content and transaminase elevations. In addition to liver
      disease, patients with LAL Deficiency experience increased risk for cardiovascular disease
      and accelerated atherosclerosis.

      The LAL Deficiency Registry is a global registry, established to help improve care for
      patients through improved understanding of the disease and long-term effectiveness of
      therapeutic interventions including sebelipase alfa.

      As with other registries, which are becoming increasingly valuable for collecting information
      in large, heterogeneous, 'real world' populations, the LAL Deficiency Registry aims to
      provide evidence to help support patient care and inform clinical practice. This Registry is
      also being conducted, in part, to fulfill post-marketing commitments and requirements agreed
      to by the Sponsor as a condition for sebelipase alfa approval in the EU and the USA.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">June 2029</completion_date>
  <primary_completion_date type="Anticipated">June 2029</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>15 Years</target_duration>
  <primary_outcome>
    <measure>Understanding of the variability, progression, identification and natural history of LAL Deficiency.</measure>
    <time_frame>Ongoing</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Lysosomal Acid Lipase Deficiency</condition>
  <condition>Cholesterol Ester Storage Disease</condition>
  <condition>Wolman Disease</condition>
  <condition>Acid Cholesteryl Ester Hydrolase Deficiency, Type 2</condition>
  <condition>Acid Lipase Deficiency</condition>
  <condition>LIPA Deficiency</condition>
  <condition>LAL-Deficiency</condition>
  <arm_group>
    <arm_group_label>LAL Deficiency patients</arm_group_label>
    <description>Patients are those with a diagnosis of LAL Deficiency (living and deceased), irrespective of treatment status or treatment choice.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with a diagnosis of LAL Deficiency.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patients must have a confirmed diagnosis of LAL Deficiency. An Informed Consent and
        Authorization must be obtained prior to patient enrollment where required under applicable
        laws and regulations, or a waiver must be obtained by the Institutional Review
        Board/Independent Ethics Committee.

        Patients cannot be currently participating in an Alexion-sponsored clinical trial. Patients
        who have concluded participation in an Alexion-sponsored sebelipase alfa clinical trial are
        eligible to enroll in this Registry, and enrollment in the Registry will not exclude a
        patient from enrolling in a future clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexion Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexion Pharmaceuticals, Inc.</last_name>
    <email>laldregistry@alexion.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Albacete</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>ZÃ¼rich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.laldeficiencyregistry.com/</url>
    <description>LAL Deficiency Registry</description>
  </link>
  <link>
    <url>http://alexion.com</url>
    <description>Alexion Website</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2012</study_first_submitted>
  <study_first_submitted_qc>July 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2012</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wolman Disease</mesh_term>
    <mesh_term>Cholesterol Ester Storage Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

